CytoSorbents Q2 adjusted loss narrows on cost controls
CytoSorbents Q2 adjusted loss narrows on cost controls
Overview
U.S. blood purification firm's Q2 revenue was flat yr/yr at $9.6 mln
Adjusted net loss per share improved yr/yr, reflecting cost controls and restructuring
Gross margin rose to 73% from 71% a year ago
Outlook
Company says it remains on track toward operating cash flow breakeven in H2 2026
CytoSorbents plans to add 3-5 sales representatives in Germany through early 2027
Company anticipates submitting a new De Novo application for DrugSorb-ATR in early 2027
Result Drivers
REGIONAL SALES MIX - Growth in distributor and strategic partner territories and direct sales outside Germany was offset by a 24% decline in Germany sales, attributed to a smaller, more focused sales force
COST CONTROLS - Improved gross margins and reduced operating losses were driven by manufacturing optimization, improved sourcing, production efficiencies, and tighter cost controls
RESTRUCTURING IMPACT - Workforce reduction and commercial restructuring, particularly in Germany, contributed to a leaner organization and lower operating cash burn
Company press release: ID:nPn74p3c8a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $9.63 mln | $9.35 mln (2 Analysts) |
Q2 Adjusted Loss Per Share | Meet | $0.05 | $0.05 (2 Analysts) |
Q2 Loss Per Share |
| $0.07 |
|
Q2 Gross Margin |
| 73.00% |
|
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Cytosorbents Corp is $2.88, about 647.3% above its August 5 closing price of $0.38
Reuters Recommended Reads
Aug 4 - Dialysis provider DaVita's Q2 results beat estimates, aided by higher average rates
Aug 5 - Netherlands' Qiagen Q2 sales flat, exceed company outlook
Aug 4 - Germany's Fresenius raises 2026 core EPS growth guidance
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)